Radotinib

Phase 3Small molecule

Radotinib is one of 2 small molecule programs targeting Chronic Myeloid Leukemia, Chronic Phase. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Myeloid Leukemia, Chronic PhaseActive, not recruiting

Chronic Myeloid Leukemia, Chronic PhasePhase 3

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Chronic Myeloid Leukemia, Chronic Phase

#DrugCompanyPhaseTrials

Radotinib Hcl

IIl-Yang Pharm. Co., Ltd.

Phase 3

1 2

Radotinib

IIl-Yang Pharm. Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Active, not recruiting

Chronic Myeloid Leukemia, Chronic Phase

NCT03722420

Clinical

Trials by Indication[1]

Philadelphia Chromosome Positive CML1 trial

Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI

Completed·IIl-Yang Pharm. Co., Ltd.·Phase 1/2·NCT01602952·85 enrolled

CML1 trial

Radotinib as 3rd or Later Line Therapy in CP-CML

Unknown status·UUlsan University Hospital·Phase 2·NCT02422719·73 enrolled

Myeloid Leukemia1 trial

Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients

Completed·IIl-Yang Pharm. Co., Ltd.·Phase 3·NCT01511289·242 enrolled

Chronic Myeloid Leukemia, Chronic Phase1 trial

A Phase III, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Chinese Patients in Chronic Phase

Active, not recruiting·IIl-Yang Pharm. Co., Ltd.·Phase 3·NCT03722420·238 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Radotinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Radotinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Radotinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Il-Yang Pharm. Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IIl-Yang Pharm. Co., Ltd.

Radotinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Philadelphia Chromosome Positive CML1 trial

CML1 trial

Myeloid Leukemia1 trial

Chronic Myeloid Leukemia, Chronic Phase1 trial

References

Drug Info

Quick Facts

Related News